Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: a systematic review

Kyla A McKay, Vivian Kwan, Thomas Duggan, Helen Tremlett, Kyla A McKay, Vivian Kwan, Thomas Duggan, Helen Tremlett

Abstract

Multiple sclerosis (MS) is a chronic central nervous system disease with a highly heterogeneous course. The aetiology of MS is not well understood but is likely a combination of both genetic and environmental factors. Approximately 85% of patients present with relapsing-remitting MS (RRMS), while 10-15% present with primary progressive MS (PPMS). PPMS is associated with an older onset age, a different sex ratio, and a considerably more rapid disease progression relative to RRMS. We systematically reviewed the literature to identify modifiable risk factors that may be associated with these different clinical courses. We performed a search of six databases and integrated twenty observational studies into a descriptive review. Exposure to Epstein-Barr virus (EBV) appeared to increase the risk of RRMS, but its association with PPMS was less clear. Other infections, such as human herpesvirus-6 and chlamydia pneumoniae, were not consistently associated with a specific disease course nor was cigarette smoking. Despite the vast literature examining risk factors for the development of MS, relatively few studies reported findings by disease course. This review exposes a gap in our understanding of the risk factors associated with the onset of PPMS, our current knowledge being predominated by relapsing-onset MS.

References

    1. Milo R., Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmunity Reviews. 2010;9(5):A387–A394. doi: 10.1016/j.autrev.2009.11.010.
    1. Kingwell E., Marriott J. J., Jetté N., et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurology. 2013;13, article 128 doi: 10.1186/1471-2377-13-128.
    1. Evans C., Beland S.-G., Kulaga S., et al. Incidence and prevalence of multiple sclerosis in the americas: a systematic review. Neuroepidemiology. 2013;40(3):195–210. doi: 10.1159/000342779.
    1. Lublin F. D., Reingold S. C., Cohen J. A., et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–286. doi: 10.1212/wnl.0000000000000560.
    1. Tremlett H., Zhao Y., Devonshire V. Natural history of secondary-progressive multiple sclerosis. Multiple Sclerosis Journal. 2008;14(3):314–324. doi: 10.1177/1352458507084264.
    1. Koch M., Kingwell E., Rieckmann P., et al. The natural history of secondary progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 2010;81(9):1039–1043. doi: 10.1136/jnnp.2010.208173.
    1. Koch M., Kingwell E., Rieckmann P., Tremlett H. The natural history of primary progressive multiple sclerosis. Neurology. 2009;73(23):1996–2002. doi: 10.1212/wnl.0b013e3181c5b47f.
    1. Tremlett H., Zhao Y., Devonshire V. Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. Journal of Neurology. 2009;256(3):374–381. doi: 10.1007/s00415-009-0039-7.
    1. McKay K. A., Jahanfar S., Duggan T., Tkachuk S., Tremlett H. Factors associated with onset, relapses or progression in multiple sclerosis: a systematic review. Journal of Toxicology and Environmental Health. In press.
    1. Hersi M., Quatch P., Krewski D. Systematic review of factors influencing the onset and progression of neurological conditions: a methodological overview. Journal of Toxicology and Environmental Health. In press.
    1. Kremenchutzky M., Cottrell D., Rice G., et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressvie-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain. 1999;122(10):1941–1949. doi: 10.1093/brain/122.10.1941.
    1. Schumacker G. A., Beebe G., Kibler R. F., et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Annals of the New York Academy of Sciences. 1965;122:552–568. doi: 10.1111/j.1749-6632.1965.tb20235.x.
    1. Poser C. M., Paty D. W., Scheinberg L. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology. 1983;13(3):227–231. doi: 10.1002/ana.410130302.
    1. McDonald W. I., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Annals of Neurology. 2001;50(1):121–127. doi: 10.1002/ana.1032.
    1. Polman C. H., Reingold S. C., Edan G., et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Annals of Neurology. 2005;58(6):840–846. doi: 10.1002/ana.20703.
    1. Lublin F. D., Reingold S. C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46(4):907–911. doi: 10.1212/wnl.46.4.907.
    1. Farrell R. A., Antony D., Wall G. R., et al. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology. 2009;73(1):32–38. doi: 10.1212/wnl.0b013e3181aa29fe.
    1. Ramroodi N., Niazi A. A., Sanadgol N., Ganjali Z., Sarabandi V. Evaluation of reactive Epstein-Barr Virus (EBV) in Iranian patient with different subtypes of multiple sclerosis (MS) The Brazilian Journal of Infectious Diseases. 2013;17(2):156–163. doi: 10.1016/j.bjid.2012.09.008.
    1. Munger K. L., Levin L. I., O'Reilly E. J., Falk K. I., Ascherio A. Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Multiple Sclerosis. 2011;17(10):1185–1193. doi: 10.1177/1352458511408991.
    1. Villoslada P., Juste C., Tintore M., et al. The immune response against herpesvirus is more prominent in the early stages of MS. Neurology. 2003;60(12):1944–1948. doi: 10.1212/01.wnl.0000069461.53733.f7.
    1. Yea C., Tellier R., Chong P., et al. Epstein-barr virus in oral shedding of children with multiple sclerosis. Neurology. 2013;81(16):1392–1399. doi: 10.1212/wnl.0b013e3182a841e4.
    1. Ahram M., El-Omar A., Baho Y., Lubad M. A. Association between human herpesvirus 6 and occurrence of multiple sclerosis among Jordanian patients. Acta Neurologica Scandinavica. 2009;120(6):430–435. doi: 10.1111/j.1600-0404.2009.01187.x.
    1. Mayne M., Krishnan J., Metz L., et al. Infrequent detection of human herpesvirus 6 DNA in peripheral blood mononuclear cells from multiple sclerosis patients. Annals of Neurology. 1998;44(3):391–394. doi: 10.1002/ana.410440317.
    1. Soldan S. S., Berti R., Salem N., et al. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nature Medicine. 1997;3(12):1394–1397. doi: 10.1038/nm1297-1394.
    1. Rodríguez-Violante M., Ordoñez G., Bermudez J. R., Sotelo J., Corona T. Association of a history of varicella virus infection with multiple sclerosis. Clinical Neurology and Neurosurgery. 2009;111(1):54–56. doi: 10.1016/j.clineuro.2008.07.007.
    1. Mancuso R., Saresella M., Hernis A., et al. Torque teno virus (TTV) in multiple sclerosis patients with different patterns of disease. Journal of Medical Virology. 2013;85(12):2176–2183. doi: 10.1002/jmv.23707.
    1. Munger K. L., Peeling R. W., Hernán M. A., et al. Infection with Chlamydia pneumoniae and risk of multiple sclerosis. Epidemiology. 2003;14(2):141–147. doi: 10.1097/00001648-200303000-00006.
    1. Munger K. L., DeLorenze G. N., Levin L. I., et al. A prospective study of Chlamydia pneumoniae infection and risk of MS in two US cohorts. Neurology. 2004;62(10):1799–1803. doi: 10.1212/01.wnl.0000125193.58601.2c.
    1. Krametter D., Niederwieser G., Berghold A., et al. Chlamydia pneumoniae in multiple sclerosis: humoral immune responses in serum and cerebrospinal fluid and correlation with disease activity marker. Multiple Sclerosis. 2001;7(1):13–18. doi: 10.1191/135245801676514804.
    1. Alonso A., Jick S. S., Jick H., Hernán M. A. Antibiotic use and risk of multiple sclerosis. American Journal of Epidemiology. 2006;163(11):997–1002. doi: 10.1093/aje/kwj123.
    1. Alonso Á., Jick S. S., Olek M. J., Ascherio A., Jick H., Hernán M. A. Recent use of oral contraceptives and the risk of multiple sclerosis. Archives of Neurology. 2005;62(9):1362–1365. doi: 10.1001/archneur.62.9.1362.
    1. Hernán M. A., Jick S. S., Logroscino G., Olek M. J., Ascherio A., Jick H. Cigarette smoking and the progression of multiple sclerosis. Brain. 2005;128(6):1461–1465. doi: 10.1093/brain/awh471.
    1. Manouchehrinia A., Tench C. R., Maxted J., Bibani R. H., Britton J., Constantinescu C. S. Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. Brain. 2013;136, part 7:2298–2304.
    1. Sundström P., Nyström L. Smoking worsens the prognosis in multiple sclerosis. Multiple Sclerosis. 2008;14(8):1031–1035. doi: 10.1177/1352458508093615.
    1. Runmarker B., Andersen O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain. 1995;118(1):253–261. doi: 10.1093/brain/118.1.253.
    1. Sadovnick A. D., Duquette P., Herrera B., Yee I. M. L., Ebers G. C. A timing-of-birth effect on multiple sclerosis clinical phenotype. Neurology. 2007;69(1):60–62. doi: 10.1212/01.wnl.0000265053.22905.64.
    1. Wigle D. T., Turner M. C., Krewski D. A systematic review and meta-analysis of childhood leukemia and parental occupational pesticide exposure. Environmental Health Perspectives. 2009;117(10):1505–1513. doi: 10.1289/ehp.0900582.
    1. Chan P. K. S., Tam W.-H., Yeo W., Cheung J. L. K., Zhong S., Cheng A. F. High carriage rate of TT virus in the cervices of pregnant women. Clinical Infectious Diseases. 2001;32(9):1376–1377. doi: 10.1086/319983.
    1. Rocchi J., Ricci V., Albani M., et al. Torquetenovirus DNA drives proinflammatory cytokines production and secretion by immune cells via toll-like receptor 9. Virology. 2009;394(2):235–242. doi: 10.1016/j.virol.2009.08.036.
    1. Grigoriadis N., Hadjigeorgiou G. M. Virus-mediated autoimmunity in multiple sclerosis. Journal of Autoimmune Diseases. 2006;3, article 1 doi: 10.1186/1740-2557-3-1.
    1. Ascherio A., Munger K. L. Epstein-barr virus infection and multiple sclerosis: a review. Journal of Neuroimmune Pharmacology. 2010;5(3):271–277. doi: 10.1007/s11481-010-9201-3.
    1. Handel A. E., Williamson A. J., Disanto G., Dobson R., Giovannoni G., Ramagopalan S. V. Smoking and multiple sclerosis: an updated meta-analysis. PLoS ONE. 2011;6(1) doi: 10.1371/journal.pone.0016149.e16149
    1. Tremlett H., Zhao Y., Rieckmann P., Hutchinson M. New perspectives in the natural history of multiple sclerosis. Neurology. 2010;74(24):2004–2015. doi: 10.1212/wnl.0b013e3181e3973f.
    1. Torkildsen Ø., Grytten N., Aarseth J., Myhr K.-M., Kampman M. T. Month of birth as a risk factor for multiple sclerosis: an update. Acta Neurologica Scandinavica. 2012;126(195):58–62. doi: 10.1111/ane.12040.
    1. Fiddes B., Wason J., Kemppinen A., Ban M., Compston A., Sawcer S. Confounding underlies the apparent month of birth effect in multiple sclerosis. Annals of Neurology. 2013;73(6):714–720. doi: 10.1002/ana.23925.
    1. Dwan K., Altman D. G., Arnaiz J. A., et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS ONE. 2008;3(8) doi: 10.1371/journal.pone.0003081.e3081

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する